NASDAQ:OPGN - OpGen Stock Price, Forecast & News

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

OpGen's stock reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

OpGen Inc (NASDAQ:OPGN) posted its quarterly earnings results on Wednesday, November, 6th. The medical research company reported ($3.34) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($2.60) by $0.74. The medical research company had revenue of $0.65 million for the quarter, compared to analysts' expectations of $0.90 million. OpGen had a negative return on equity of 662.90% and a negative net margin of 397.44%. View OpGen's Earnings History.

OpGen is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for OpGen.

OpGen issued an update on its FY 2019 After-Hours earnings guidance on Wednesday, February, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.5-3.5 million, compared to the consensus revenue estimate of $3.55 million.

3 Wall Street analysts have issued 12 month price targets for OpGen's shares. Their forecasts range from $1.50 to $20.00. On average, they anticipate OpGen's share price to reach $7.93 in the next twelve months. This suggests a possible upside of 366.7% from the stock's current price. View Analyst Price Targets for OpGen.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OpGen.

News headlines about OPGN stock have trended very negative on Wednesday, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. OpGen earned a news impact score of -3.7 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for OpGen.

OpGen saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 80,900 shares, a drop of 61.7% from the January 15th total of 211,200 shares. Based on an average daily volume of 865,400 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.5% of the company's stock are sold short. View OpGen's Current Options Chain.

Some companies that are related to OpGen include Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS) and Aeon Global Health (AGHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), vTv Therapeutics (VTVT), Energy Transfer LP Unit (ET), Nabriva Therapeutics (NBRV), Vaxart (VXRT), Protalix Biotherapeutics (PLX), TrovaGene (TROV) and Melinta Therapeutics (MLNT).

(OPGN) raised $17 million in an initial public offering (IPO) on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.

OpGen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.22%), Virtu Financial LLC (0.96%) and Oxford Asset Management LLP (0.41%). View Institutional Ownership Trends for OpGen.

OPGN stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Renaissance Technologies LLC and Oxford Asset Management LLP. View Insider Buying and Selling for OpGen.

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OPGN stock can currently be purchased for approximately $1.70.

OpGen has a market capitalization of $9.52 million and generates $2.95 million in revenue each year. The medical research company earns $-13,370,000.00 in net income (profit) each year or ($44.40) on an earnings per share basis. OpGen employs 44 workers across the globe.View Additional Information About OpGen.

The official website for OpGen is http://www.opgen.com/.

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected]